LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 1 of total 1

Search options

Article ; Online: Cerebrolysin for acute ischaemic stroke.

Ziganshina, Lilia E / Abakumova, Tatyana / Kuchaeva, Alexandra

The Cochrane database of systematic reviews

2010  , Issue 4, Page(s) CD007026

Abstract: Background: Cerebrolysin is a mixture of low-molecular-weight peptides and amino acids derived from pigs' brain tissue which has proposed neuroprotective and neurotrophic properties. It is widely used in the treatment of acute ischaemic stroke in Russia ...

Abstract Background: Cerebrolysin is a mixture of low-molecular-weight peptides and amino acids derived from pigs' brain tissue which has proposed neuroprotective and neurotrophic properties. It is widely used in the treatment of acute ischaemic stroke in Russia and China.
Objectives: To assess the benefits and risks of cerebrolysin for treating acute ischaemic stroke.
Search strategy: We searched the Cochrane Stroke Group Trials Register (February 2009), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 1, 2009), MEDLINE (1966 to February 2009), EMBASE (1974 to February 2009), LILACS (1982 to February 2009), Science Citation Index (1940 to February 2009), SIGLE Archive (1980 to March 2005), and a number of relevant Russian Databases (1988 to February 2009). We also searched reference lists, ongoing trials registers and conference proceedings.
Selection criteria: Randomised controlled trials comparing cerebrolysin with placebo or no treatment in patients with acute ischaemic stroke.
Data collection and analysis: Three review authors independently applied the inclusion criteria, assessed trial quality and extracted the data.
Main results: We included one trial involving 146 participants. There was no difference in death (6/78 in the cerebrolysin group versus 6/68 in the placebo group; risk ratio (RR) 0.87, 95% confidence interval (CI) 0.29 to 2.58) or in the total number of adverse events (16.4% versus 10.3%; RR 1.62, 95% CI 0.69 to 3.82) between the treatment and control groups.
Authors' conclusions: There is not enough evidence to evaluate the effect of cerebrolysin on survival and dependency in people with acute ischaemic stroke. High-quality and large-scale randomised controlled trials may help to gain a better understanding of the potential value of cerebrolysin in acute ischaemic stroke.
MeSH term(s) Amino Acids/therapeutic use ; Humans ; Neuroprotective Agents/therapeutic use ; Stroke/drug therapy
Chemical Substances Amino Acids ; Neuroprotective Agents ; cerebrolysin (37KZM6S21G)
Language English
Publishing date 2010-04-14
Publishing country England
Document type Journal Article ; Review ; Systematic Review
ISSN 1469-493X
ISSN (online) 1469-493X
DOI 10.1002/14651858.CD007026.pub2
Database MEDical Literature Analysis and Retrieval System OnLINE

More links

Kategorien

To top